2-Fluoro-2-deoxy-D-glucose

Overview
Catalog #	bs-76317c-25mg
Product Name	2-Fluoro-2-deoxy-D-glucose
Specifications
Storage Buffer	Powder
Storage Condition	Stable for 2 years after receipt when stored at -20°C.
Target
Product Information	CAS Number: 29702-43-0 Molecular formula: C6H11FO5 Molecular weight: 182.15 Purity: >97% (NMR) Appearance: White to yellow powder. Solubility: Soluble in DMF (30mg/ml), DMSO (30mg/ml) or water (10mg/ml). InChiKey: ZCXUVYAZINUVJD-IVMDWMLBSA-N SMILES: O[C@H]1C(F)C(O)[C@H](O)[C@@H](CO)O1 SMILES: OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](F)C=O
Description	2-Fluoro-2-deoxy-D-glucose [FDG] is a glucose analog that inhibits cellular glycosylation. It is the natural isotope-form of 18F-FDG that can be taken up by cells but does not undergo metabolic glycolysis. FDG uptake is closely related to the expression of the glucose transporter (GLUT) in malignant tumours. FDG is also a substrate of hexokinase isozymes and an inhibitor of cellular glycosylation. FDG is taken up by high-glucose-using cells such as brain, brown adipocytes, kidney and cancer cells, where phosphorylation prevents the glucose from being released again from the cell, once it has been absorbed. The 2-hydroxyl group (–OH) in normal glucose is needed for further glycolysis (metabolism of glucose by splitting it), but FDG is missing this 2-hydroxyl and cannot be further metabolized in cells. FDG is used in positron emission tomography (PET) as contrast agent and is the most widely used PET marker. FDG-PET can be used for diagnosis, staging, and monitoring treatment of cancers, particularly in Hodgkin's disease, non-Hodgkin lymphoma, colorectal cancer, breast cancer, melanoma, and lung cancer. FDG has also anticancer and chemosensitizing activity.